Dandelion Health Raises $14 Million in Series A Funding

Dandelion Health, a New York-based clinical intelligence platform for life sciences, has raised $14 million in Series A funding.

Healthier Capital led the round. Colle Capital joined the raise, along with existing backers Primary Venture Partners, Moxxie Ventures, and Convergent Ventures.

The company said the fresh capital will support its expansion in pharmaceutical drug development. It also plans to strengthen its data infrastructure and grow partnerships across the pharma sector.

What Dandelion Health does

Led by CEO Elliott Green, Dandelion Health provides a clinical intelligence platform that serves life sciences companies across the drug development lifecycle.

Its multimodal data infrastructure covers 73 hospitals, more than 15 million patients, and eight petabytes of structured, unstructured, and raw biological data. The platform is designed to help pharmaceutical companies build more precise trials, identify biomarkers, and generate real-world evidence.

Why the raise matters

The funding comes as drug developers continue to look for better data tools to support research, trial design, and commercialization.

Dandelion Health’s platform sits at the intersection of clinical data and pharmaceutical decision-making. That positioning may support broader use across discovery, development, and post-launch activities.

The company said it works with partners across the full drug development lifecycle, from discovery through commercialization.